Journal of liver cancer最新文献_第2页

Correspondence to editorial on "Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea". 与“韩国肝细胞癌流行病学、病因学和治疗模式的发展趋势”的社论对应。

Journal of liver cancer Pub Date : 2025-03-01 Epub Date: 2025-02-27 DOI: 10.17998/jlc.2025.02.17

Ji Won Han, Bo Hyun Kim

引用次数: 0

Microwave ablation vs. liver resection for patients with hepatocellular carcinomas. 微波消融与肝切除术治疗肝细胞癌的疗效比较。

Journal of liver cancer Pub Date : 2025-03-01 Epub Date: 2025-02-07 DOI: 10.17998/jlc.2025.02.02

Hyundam Gu, Yeonjoo Seo, Dong Jin Chung, Kwang Yeol Paik, Seung Kew Yoon, Jihye Lim

{"title":"Microwave ablation vs. liver resection for patients with hepatocellular carcinomas.","authors":"Hyundam Gu, Yeonjoo Seo, Dong Jin Chung, Kwang Yeol Paik, Seung Kew Yoon, Jihye Lim","doi":"10.17998/jlc.2025.02.02","DOIUrl":"10.17998/jlc.2025.02.02","url":null,"abstract":"Backgrounds/aims: Microwave ablation (MWA) is an emerging ablative therapy that surpasses previous methods by achieving higher temperatures and creating larger ablation zones within shorter periods. This study compared the therapeutic outcomes of MWA with those of liver resection in real-world clinical practice.Methods: A total of 178 patients with 259 nodules who underwent MWA or liver resection between January 2015 and July 2023 were enrolled. Local tumor progression (LTP)-free survival, overall progression (OP)-free survival, and overall survival (OS) were assessed based on the treatment modality for the index nodule.Results: Of the 178 patients, 134 with 214 nodules underwent MWA, and 44 with 45 nodules underwent liver resection. The median follow-up period was 2.0±1.5 years. The annual incidence of LTP was 3.7% for MWA and 1.4% for liver resection. Treatment modality did not significantly affect LTP-free survival (hazard ratio, 0.61; 95% confidence interval, 0.14-2.69; P=0.511). For nodules larger than 3 cm, LTP-free survival was not affected by the treatment modality. Similarly, OP-free survival and OS were not influenced by treatment modality.Conclusions: MWA and liver resection demonstrated comparable treatment outcomes in terms of local tumor control, overall recurrence, and survival. MWA may be an alternative treatment option for select patients; however, further studies are necessary to generalize these findings.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"99-108"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhanced radiofrequency ablation for recurrent hepatocellular carcinoma post-transarterial chemoembolization: a prospective study utilizing twin internally cooled-perfusion electrodes. 强化射频消融治疗复发性肝癌经动脉化疗栓塞后：一项利用双内冷灌注电极的前瞻性研究。

Journal of liver cancer Pub Date : 2025-03-01 Epub Date: 2025-02-07 DOI: 10.17998/jlc.2025.01.25

Sungjun Hwang, Jae Hyun Kim, Sae-Jin Park, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong Min Lee

{"title":"Enhanced radiofrequency ablation for recurrent hepatocellular carcinoma post-transarterial chemoembolization: a prospective study utilizing twin internally cooled-perfusion electrodes.","authors":"Sungjun Hwang, Jae Hyun Kim, Sae-Jin Park, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong Min Lee","doi":"10.17998/jlc.2025.01.25","DOIUrl":"10.17998/jlc.2025.01.25","url":null,"abstract":"Backgrounds/aims: Radiofrequency ablation (RFA) is widely employed for managing recurrent hepatocellular carcinoma (HCC) following transarterial chemoembolization (TACE). However, local tumor progression (LTP) after treatment remains a significant challenge. This study evaluates the efficacy of saline-perfused bipolar RFA using twin internally cooled-perfusion (TICP) electrodes in managing recurrent HCC post-TACE.Methods: Between September 2017 and January 2019, 100 patients with 105 nodules (mean diameter, 1.6±0.5 cm) were prospectively enrolled. Bipolar RFA with TICP electrodes was performed under ultrasound-computed tomography/magnetic resonance fusion guidance. The primary outcome was the 2-year cumulative incidence of LTP.Results: The technical success and technique efficacy rates were 100% and 97%, respectively. During a median follow-up period of 34.0 months (range, 3-41), the estimated LTP rates were 13.3% at 1 year and 17.7% at 2 years. Progression-free survival rates were 37.8% and 27.7% at 1 year and 2 years, respectively.Conclusions: Saline-perfused bipolar RFA using TICP electrodes demonstrates promising results for recurrent HCC after TACE, achieving high technical success and effective local tumor control rates.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"91-98"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of new biomarkers of hepatic cancer stem cells through proteomic profiling. 通过蛋白质组学分析鉴定肝癌干细胞新的生物标志物。

Journal of liver cancer Pub Date : 2025-03-01 Epub Date: 2025-03-20 DOI: 10.17998/jlc.2025.03.08

Sung Hoon Choi, Ha Young Lee, Sung Ho Yun, Sung Jae Jang, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim

{"title":"Identification of new biomarkers of hepatic cancer stem cells through proteomic profiling.","authors":"Sung Hoon Choi, Ha Young Lee, Sung Ho Yun, Sung Jae Jang, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim","doi":"10.17998/jlc.2025.03.08","DOIUrl":"10.17998/jlc.2025.03.08","url":null,"abstract":"Backgrounds/aims: In hepatocellular carcinoma (HCC), which exhibits high mortality and recurrence rates globally, the traits of cancer stem cells (CSCs) that significantly influence recurrence and metastasis are not well understood. CSCs are self-renewing cell types identified in most liquid and solid cancers, contributing to tumor initiation, growth, resistance, recurrence, and metastasis following chemo-radiotherapy or trans-arterial chemoembolization therapy.Methods: CSCs are classified based on the expression of cell surface markers such as CD133, which varies depending on the tumor type. Proteomic analysis of liver cancer cell lines with cancer stem cell potential and HCC cancer cell lines lacking stem cell propensity was conducted to compare and analyze specific expression patterns.Results: Proteomic profiling and enrichment analysis revealed higher expression of the calcium-binding protein S100 family in CD133+ Huh7 cells than in CD133- or wild-type cells. Furthermore, elevated expression of S100 family members was confirmed in an actual CD133+ liver cancer cell line via protein-protein network analysis and quantitative polymerase chain reaction (qPCR).Conclusion: The S100 family members are not only new markers of cancer stem cells but will also assist in identifying new treatment strategies for CSC metastasis and tumor advancement.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"123-133"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report. 门静脉肿瘤血栓形成肝细胞癌患者停用阿特珠单抗-贝伐单抗治疗后的持久完全应答：首次报告。

Journal of liver cancer Pub Date : 2025-03-01 Epub Date: 2024-11-05 DOI: 10.17998/jlc.2024.09.26

Pramod Kumar, Pradeep Krishna, Rohit Maidur, Naveen Chandrashekhar, Suresh Raghavaiah

引用次数: 0

Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea. 韩国肝细胞癌流行病学、病因学和治疗模式的发展趋势。

Journal of liver cancer Pub Date : 2025-03-01 Epub Date: 2024-12-05 DOI: 10.17998/jlc.2024.12.04

Soo Young Hwang, Ju Dong Yang

引用次数: 0

Superselective ablative chemo-ethanol embolization for recurrent single hepatocellular carcinoma: a 6-month outcome analysis. 超选择性消融化疗乙醇栓塞治疗复发性单肝细胞癌：六个月疗效分析。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-05-14 DOI: 10.17998/jlc.2024.05.08

Jae Hwan Lee, Kun Yung Kim, Chong-Ho Lee, Minuk Kim, Chang Jin Yoon

{"title":"Superselective ablative chemo-ethanol embolization for recurrent single hepatocellular carcinoma: a 6-month outcome analysis.","authors":"Jae Hwan Lee, Kun Yung Kim, Chong-Ho Lee, Minuk Kim, Chang Jin Yoon","doi":"10.17998/jlc.2024.05.08","DOIUrl":"10.17998/jlc.2024.05.08","url":null,"abstract":"Backgrounds/aims: To evaluate the safety and effectiveness of superselective ablative chemo-ethanol embolization (SACE) for the treatment of patients with recurrent single hepatocellular carcinoma (rHCC).Methods: This retrospective study included 22 patients (19 men; median age, 63 years [range, 38-86]) with Child-Pugh class of A/ B/C (16/3/3) that underwent SACE between January and June 2023 for recurrent single HCCs measuring ≤5 cm in diameter using a mixture of 99% ethanol and ethiodized oil/doxorubicin emulsion. The primary endpoint was the 6-month tumor response, and the secondary endpoints were the 1-month tumor response and treatment-related safety. This study was approved by our institutional review board, and the requirement for informed consent was waived.Results: SACE was successfully performed in 22 patients (95.2%). The complete response rates at 1-month and 6-month after treatment were 100.0% and 83.3%, respectively. At 6-month, local tumor progression occurred in one patient and intrahepatic distant metastasis was found in six patients (30.0%). No 6-month mortalities were reported. No adverse events greater than grade 2 or laboratory deteriorations were observed. Biliary complications or liver abscesses were not observed.Conclusions: SACE for a single rHCC was highly effective in achieving a favorable 6-month tumor response and showed acceptable adverse events. However, further prospective studies are required to verify these findings.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"217-223"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment. 大量吸烟会增加肝细胞癌患者治愈后的早期死亡风险。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-06-07 DOI: 10.17998/jlc.2024.06.02

Jaejun Lee, Jong Young Choi, Soon Kyu Lee

{"title":"Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment.","authors":"Jaejun Lee, Jong Young Choi, Soon Kyu Lee","doi":"10.17998/jlc.2024.06.02","DOIUrl":"10.17998/jlc.2024.06.02","url":null,"abstract":"Backgrounds/aims: Although cigarette smoking has been associated with an increased risk of hepatocellular carcinoma (HCC), its association with HCC mortality remains underexplored. We aimed to evaluate the effect of smoking on early mortality in HCC patients following curative treatment.Methods: Data from the Korean Primary Liver Cancer Registry were examined for HCC patients who underwent liver resection or radiofrequency ablation between 2015 and 2018. Smoking cumulative dose was assessed in pack-years. The primary outcome was the 3-year overall survival (OS).Results: Among 1,924 patients, 161 were classified as heavy smokers (≥40 pack-years). Heavy smokers exhibited a lower 3-year survival rate (77.1%) than nonsmokers (83.3%), with a significant difference observed in the 3-year OS (P=0.016). The assessment of smoking pack-years in relation to 3-year OS revealed a dose-dependent pattern, with the hazard ratio exceeding 1.0 at 20 pack-years and continuing to rise until 40 pack-years, reaching peak at 1.21 (95% confidence interval, 1.01-1.45). Multivariate Cox-regression analysis revealed heavy smoking, age ≥60 years, underlying cirrhosis, tumor size >3 cm, vascular invasion, and Child-Pugh class B/C as risk factors for 3-year OS. Subgroup analyses of patients with a tumor size <3 cm, absence of vascular invasion, and meeting the Milan criteria also showed inferior outcomes for heavy smokers in all three subgroups.Conclusions: Heavy smoking, defined as a history of >40 pack-years, was linked to poorer 3-year survival outcomes in HCC patients undergoing curative treatments, underscoring the importance of smoking cessation in this population.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"253-262"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141297617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New systemic treatment options for advanced cholangiocarcinoma. 晚期胆管癌的新系统治疗方案。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.17998/jlc.2024.08.07

Valentina Zanuso, Giulia Tesini, Elena Valenzi, Lorenza Rimassa

{"title":"New systemic treatment options for advanced cholangiocarcinoma.","authors":"Valentina Zanuso, Giulia Tesini, Elena Valenzi, Lorenza Rimassa","doi":"10.17998/jlc.2024.08.07","DOIUrl":"10.17998/jlc.2024.08.07","url":null,"abstract":"Cholangiocarcinoma (CCA) is a rare and aggressive cancer, mostly diagnosed at advanced or metastatic stage, at which point systemic treatment represents the only therapeutic option. Chemotherapy has been the backbone of advanced CCA treatment. More recently, immunotherapy has changed the therapeutic landscape, as immune checkpoint inhibitors have yielded the first improvement in survival and currently, the addition of either durvalumab or pembrolizumab to standard of care cisplatin plus gemcitabine represents the new first-line treatment option. However, the use of immunotherapy in subsequent lines has not demonstrated its efficacy and therefore, it is not approved, except for pembrolizumab in the selected microsatellite instability-high population. In addition, advances in comprehensive genomic profiling have led to the identification of targetable genetic alterations, such as isocitrate dehydrogenase 1 (IDH1), fibroblast growth factor receptor 2 (FGFR2), human epidermal growth factor receptor 2 (HER2), proto-oncogene B-Raf (BRAF), neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), Kirsten rat sarcoma virus (KRAS), and mouse double minute 2 homolog (MDM2), thus favoring the development of a precision medicine approach in previously treated patients. Despite these advances, the use of molecularly driven agents is limited to a subgroup of patients. This review aims to provide an overview of the newly approved systemic therapies, the ongoing studies, and future research challenges in advanced CCA management.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"155-170"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma. 探索肝切除术作为多结节 BCLC-A 型肝癌一线治疗方案的作用。

Journal of liver cancer Pub Date : 2024-09-01 Epub Date: 2024-08-16 DOI: 10.17998/jlc.2024.08.08

Joo Hyun Oh, Dong Hyun Sinn

引用次数: 0